It’s all over social media: the Shenzhen-Zhongshan Corridor, a mega-project that has captured the world’s attention, has officially opened for trial operations.

This “super corridor” serves not only as a physical connection but also as a symbolic link.

Guangzhou’s Nansha District, via the Wanqingsha Branch of the Nanzhong Expressway, connects to this “super corridor,” primarily to link diverse industries and open up channels for investment promotion.

In particular, biopharmaceuticals are a vital component of Nansha’s “Core-Morning-Sea” industrial cluster.

Guangdong Medical Valley has emerged as the “pioneer” of Nansha’s biopharmaceutical industry, attracting over 400 biopharmaceutical companies, including Boya Gene, Tiankeya, Weishibo, Yiming Bio, Kangrun Bio, and Weichun Bio.

We focus on the cutting edge of the industry, having successively facilitated the establishment of numerous high-quality enterprises covering fields such as ophthalmic surgical robots, human stem cell technology, traditional Chinese medicine decoctions, and biotechnology.

When the “Super Corridor” and the “Super Medical Valley” resonate in unison, what kind of “investment sparks” will they ignite?

What flows is not just traffic—it is industrial synergy

A nationwide "pharmaceutical valley construction boom" has swept across the country, but cultivating the biopharmaceutical industry is extremely challenging—it is not something just any city can accomplish.

However, in the pharmaceutical R&D sector, there is a well-known “Double Ten” adage: developing a new drug requires 10 years and an investment of $1 billion.

When it comes to investment promotion, the more established and mature a biopharmaceutical park is, the more it will value the breakthrough and cutting-edge nature of a company’s new technologies, as well as its focus on commercialization.

This means that simply understanding policies is no longer enough; to attract biomanufacturing enterprises, one must become a quasi-industry expert. Only by having an intimate knowledge of leading companies, market channels, and the scientific validity of projects can one successfully “facilitate” the implementation of projects.

High-tech, high-investment, high-output, high-value... Since its inception, the biopharmaceutical industry has consistently been a high-potential growth sector across regions.

In some regions, the performance of tenant companies is evaluated based on the number of talents they attract and the patents they hold—an approach that aligns with the natural laws of industry development.

When it comes to site selection, companies maintain a long list of potential locations, evaluating them across multiple dimensions and assigning “scores” to the parks they’ve assessed, all in an effort to find the optimal solution for production and operations.

As Nansha’s first national-level technology enterprise incubator, Guangdong Medical Valley focuses on the biopharmaceutical and medical device industries. It has attracted over 400 biopharmaceutical companies, fostering a biopharmaceutical industrial cluster and incubating projects with global influence.

To date, it has attracted high-quality enterprises such as Tiankeyaya, Weishibo, Yingming Biotech, Kangrun Biotech, and Weichun Biotech, covering various sub-sectors including biopharmaceuticals, high-end medical devices, gene editing, immunotherapy, and stem cells.

The opening of the Shenzhen-Zhongshan Corridor not only injects new momentum into the transportation connectivity and regional integration of the Guangdong-Hong Kong-Macao Greater Bay Area but also has a profound impact on Nansha’s economic development, industrial layout, and regional competitiveness.

With roads open, all industries thrive. The Guangdong Medical Valley Nansha Industrial Park is rejuvenated, ushering in new opportunities for investment promotion.

Located in the hub CBD of the Guangdong-Hong Kong-Macao Greater Bay Area and at the core of the five major airport clusters, the park capitalizes on major strategic opportunities presented by the Greater Bay Area, national-level new districts, and free trade zones, ensuring that industrial development and investment promotion advance in tandem.

With the opening of the “Super Corridor,” the Shenzhen-Zhongshan “30-minute living circle” and the Greater Bay Area “1-hour living circle” are gradually transforming from a development vision into a reality.

This “leapfrog advancement” will enhance the efficiency of people and goods flows across the strait, while also providing ample space for industrial synergy and multidimensional integrated development within Guangdong Medical Valley.

In the field of biomedicine, Nansha, backed by Guangzhou, possesses resource advantages in healthcare, university research, and innovation policies, making it an ideal location for biopharmaceutical companies and service institutions to establish their headquarters.

Meanwhile, Shenzhen possesses robust resources in technology and venture capital. Following the opening of the Shenzhen-Zhongshan Corridor, the Guangdong Medical Valley Nansha Industrial Park will play an increasingly significant role in fostering synergy within the biopharmaceutical industry across both sides of the strait.

It’s Not Just Transportation That’s Speeding Up—It’s Investment Attraction Too

As the saying goes, haste makes waste. But in reality, as long as preparations are thorough enough, speed can indeed lead to success.

In terms of biopharmaceutical industry clusters, the Yangtze River Delta has taken the lead, but the Greater Bay Area possesses many unique advantages, such as R&D and clinical resources, talent exchange with Hong Kong and Macao, and back-end production capabilities.

This is indeed the case. Ten years ago, when overseas biotech experts returned to China to start businesses, their first choice might have been the Yangtze River Delta or the Beijing-Tianjin-Hebei region. Now, returning researchers are paying increasing attention to the Guangdong-Hong Kong-Macao Greater Bay Area.

Domestically, biopharmaceutical industry clusters centered on the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, the Chengdu-Chongqing Economic Circle, and the central region are beginning to take shape.

Within the Guangdong-Hong Kong-Macao Greater Bay Area, driven by Guangzhou and Shenzhen, a world-class biopharmaceutical industrial cluster is rapidly emerging.

Guangdong Medical Valley, with Nansha, Guangzhou as its starting point, has expanded to surrounding areas, successively establishing a presence in Bay Area cities such as Zhuhai, Foshan, and Zhongshan, accelerating the progress of multiple projects.

This initiative not only injects new vitality into local economic development but also serves as a significant “milestone” for the high-quality development of the biopharmaceutical industry in the Greater Bay Area.

As an investment promotion partner, we precisely match the park’s investment needs with companies’ site selection requirements, helping enterprises in fields such as ophthalmic surgical robots, human stem cell technology, biotechnology, artificial intelligence, and traditional Chinese herbal medicines to establish operations in the park.

On one hand, with years of deep engagement in the Greater Bay Area, our in-depth understanding of emerging industries and expertise in high-quality development platforms have positioned us as professional site selection consultants for enterprises.

On the other hand, through channels such as our investment promotion network and XuanNai.com, we present the location factors most critical to enterprises in the most intuitive way to companies considering relocation.

In our investment promotion efforts, we remain steadfastly committed to the park’s key development priorities and assist companies in conducting site evaluations focused on long-term value. We understand both government policies and corporate needs, and possess a forward-looking perspective on the current state of relevant industries and competitive landscapes.

Furthermore, medical enterprises are both technology-intensive and capital-intensive.

Guangdong Medical Valley possesses extensive experience in this regard. Resolving a company’s funding issues is the “1” at the core of all our services; once this “1” is secured, the rest of our services simply add “0s” to it, helping medical startups eliminate concerns about funding and technology.

It is worth noting that in addition to its own experienced operational management team, which provides “one-on-one” professional services to enterprises, Guangdong Medical Valley also boasts a “star-studded” team of expert advisors. This team includes experts with extensive experience in medical investment, as well as professors researching cutting-edge medical technologies and leaders from industry associations.

Once companies move into the park, they can enjoy “one-stop” services covering everything from product R&D to market launch, and from industrial support to financing services. This approach minimizes operational costs while enhancing service efficiency and the success rate of project incubation.

This time, the potential energy brought by the “Super Corridor” to cities on both sides of the Pearl River Estuary extends far beyond mere transportation convenience. As Nansha occupies a central position within the Greater Bay Area, it is surrounded by all 11 cities of the region and five major international airports within a 100-kilometer radius, making it a crucial hub connecting the urban clusters on both sides of the Pearl River Estuary with the Hong Kong and Macao regions.

As a key “growth pole” for the development of the biopharmaceutical and medical device industries, Guangdong Medical Valley will help Nansha build a comprehensive technology and industrial ecosystem that integrates innovation and R&D, technology transfer, industrial incubation, tech finance, and talent cultivation—covering the entire chain, all elements, and the entire process.

The convergence of the “Super Corridor” and the “Super Medical Valley” connects not only the eastern and western banks of the Pearl River Estuary but also the grand vision and future of industrial development and economic growth.